Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P045. Gene expression of discs large homologue 5 gene (DLG5) in ulcerative colitis patients
P045. Mycobacterium avium subsp. paratuberculosis survival in macrophages from inflammatory bowel disease patients
Authors:

N. Nazareth1, F. Magro2, R. Appelberg3, F. Vilas-Boas2, G. Macedo2, A. Sarmento1, 1University Fernando Pessoa, Faculty of Health Sciences, Porto, Portugal, 2Hospital de São João, Gastroenterology Department, Porto, Portugal, 3Institute for Molecular and Cell Biology (IBMC), Microbiology and Immunology of Infection, Porto, Portugal

P045

Quality of Life and Coping Mechanisms in patients with Crohn's Disease treated with Biological Therapy.

Authors:

E. Geccherle*1, M. Fortuna2, R. Montanari3, A. Geccherle3

1Padova University, Department of General Psychology, Padova, Italy, 2San Camillo Hospital, Department of Gastroenterology, Trento (TN), Italy, 3Sacro Cuore Don Calabria Negrar Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit), Department of Gastroenterology,, Negrar (VR), Italy

P046.

Lymphocytic and collagenous colitis: two clinically similar entities but with a distinct immunological pattern

Authors:

A. Carrasco1, M. Esteve1, E. Pedrosa1, M. Rosinach1, M. Aceituno1, X. Andújar1, C. Loras1, Y. Zabana1, M. Forné1, A. Salas2, F. Fernández-Bañares1, 1Hospital Universitari Mútua Terrassa. UB, Gastroenterology, Terrassa, Spain, 2Hospital Universitari Mútua Terrassa, UB, Pathology, Terrassa, Spain

P046. Differential expression of microRNAs in inflamed colonic mucosa of patients with ulcerative colitis
P046. In vivo T2 relaxometry to assess inflammation and fibrosis in a murine model of inflammatory bowel diseases
P046. Mucosal immune activation in diarrhea-predominant irritable bowel syndrome: comparison with health controls and ulcerative colitis
Authors:

C.H. Choi1, J.Y. Ahn1, K.H. Lee1, J.W. Kim1, S.K. Chang1, 1Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea

P046

CD99 and cyclophilin A correlate differently in patients with inflammatory bowel diseases

Authors:

M. Wlodarczyk*1, A. Sobolewska1, M. Cichalewska2, J.-P. Timmermans3, K. Stec-Michalska1, M. Mycko2, J. Fichna4, M. Wisniewska-Jarosinska1, A. Piechota-Polanczyk4

1Medical University of Lodz, Department of Gastroenterology, Lodz, Poland, 2Medical University of Lodz, Laboratory of Neuroimmunology, Department of Neurology, Lodz, Poland, 3University of Antwerp, Laboratory of Cell Biology and Histology, Department of Veterinary Sciences, Antwerp, Belgium, 4Medical University of Lodz, Department of Biochemistry, Lodz, Poland

P047.

Involvement of PSGL1 and its ligands P-, E- and L-selectins in inflammatory bowel disease (IBD)

Authors:

A. Pérez-Frías1, M.E. Fernández-Contreras2, R. González-Tajuelo1, P.M. Linares2, M. Guijarro-Rojas3, A. Algaba4, M. Chaparro2, J.P. Gisbert2, A. Urzainqui1, 1Hospital Universitario de La Princesa and IP, Immunology Unit, Madrid, Spain, 2Hospital Universitario de La Princesa, IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 3Hospital Universitario de La Princesa and IP, Pathology Unit, Madrid, Spain, 4Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Fuenlabrada, Spain

P047. Differential effects of TLR‑2 heterodimers activation in healthy and inflamed colon in mice
P047. Metformin inhibits NF-κB signaling in intestinal epithelial cells, and ameliorates experimental colitis and colitis-associated colon cancer in mice
Authors:

S.-J. Koh1, J.M. Kim2, J.P. Im3, C. Lee3, H.C. Jung3, J.S. Kim3, 1Seoul National University Boramae Hospital, Seoul Korea, Internal Medicine, Seoul, South Korea, 2Hanyang University College of Medicine, Seoul, South Korea, 3Seoul National University College of Medicine, Internal Medicine, Seoul, South Korea

P047. Relation between endoscopic and histological activity of the intestinal inflammatory bowel disease (IBD) and angiogenic and lymphangiogenic factors
P047

The presence of primary sclerosing cholangitis does not change levels of gut barrier failure biomarkers (I - FABP and ccK18) in patients with ulcerative colitis

Authors:

P. Drastich*1, L. Bajer1, M. Kverka2, S. Coufal2, J. Brezina1, J. Spicak1, H. Tlaskalova - Hogenova2

1Instutute of clinical and experimental medicine, Hepatogastroenterology, Prague, Czech Republic, 2The Academy of Sciences of the Czech Republic, Institute of Microbiology, Prague, Czech Republic

P048.

In vitro pancreas toxicity by azathioprine but not 6-mercaptopurine

Authors:

M. Broekman, H.M. Roelofs, F. Hoentjen, T. Demir, W.H. Peters, G.J. Wanten, D.J. de Jong, Radboud UMC, Gastroenterology & Hepatology, Nijmegen, Netherlands

P048. Decreased SHIP1 activity in Crohn's disease
P048. Metallothionein, an emerging danger signal during experimental colitis
Authors:

L. Devisscher1, P. Hindryckx1, K. Olivier1, H. Peeters1, M. Lynes2, C. Cuvelier3, M. De Vos1, D. Laukens2, 1Ghent University, Department of Gastroenterology, Ghent, Belgium, 2University of Connecticut, Department of Molecular and Cell Biology, Connecticut, United States, 3Ghent University, Department of Pathology, Ghent, Belgium

P048. Relation between angio- and lymphangiogenic factor levels and the behaviour, activity, treatment and acute phase reactants (APR) in patients with inflammatory bowel disease (IBD)
P048

The peripheral pool of gut-homing CD4+beta7+ T-cells and regulatory CD4+FoxP3+ T-cells is maintained in Crohn's disease patients with small bowel inflammation

Authors:

U. Kopylov*1, A. Lahat2, N. Levhar2, S. Neuman2, D. Yablecovitch2, B. Ungar1, R. Eliakim2, S. Ben-Horin2

1Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 2Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel

P049.

Investigation into the binding affinity of certolizumab pegol to FcRn and functional consequences for FcRn-mediated transcytosis: comparison to infliximab, adalimumab and etanercept

Authors:

T. Baker, L. Kevorkian, A. Nesbitt, UCB Pharma, Slough, United Kingdom

P049. A possible role of mucosal cytokine profile for predicting response to infliximab therapy in ulcerative colitis